GlobeNewswire·Oct 28, 2025, 7:00 AM ET

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board

AC Immune SA appointed Prof. Catherine Mummery as Chair of its Clinical Advisory Board on October 28, 2025.
Prof. Mummery leads the cognitive disorders service at the UK's National Hospital for Neurology and Neurosurgery and heads novel therapeutics at the Dementia Research Centre at University College London.
She has served as a senior investigator on over 20 early-stage studies for disease-modifying dementia agents, including the first gene silencing therapy for Alzheimer's.
Prof. Mummery was an investigator on AC Immune's Phase 1b/2a trial for candidate ACI-35.030 (JNJ-2056).
Her role will involve advising on the company's pipeline, including active immunotherapies in Phase 2 and novel small molecules targeting intracellular mechanisms such as ACI-19764.
The Clinical Advisory Board also includes Dr. Reisa Sperling, Dr. Murat Emre, Dr. Lon Schneider, Dr. Pierre Tariot, and Dr. Juan Fortea.
Dr. Kaj Blennow, the previous Chairman, is retiring from the board.
AC Immune operates with SupraAntigen® and Morphomer® technology platforms to develop precision prevention therapies for neurodegenerative diseases.
The company has secured partnerships resulting in potential milestone payments and royalties exceeding $4.5 billion.